Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01345864 · ClinicalTrials.gov registry record · Phase 1
Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT01345864 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 88 participants.
The verdict
NCT01345864, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
This study is designed to look at the potential for an investigational drug (PF-04995274, under development by Pfizer, Inc. as a potential treatment for Alzheimer's disease) to reverse changes in memory and learning/problem solving skills caused by co-administration of a marketed drug called scopolamine. Scopolamine is known to cause temporary changes in memory and learning/problem solving skills that are similar to those seen in people with alzheimer's disease(AD).
Interventions
- DRUG Scopolamine + Donepezil Placebo + PF-04995274 Placebo
- DRUG Scopolamine + Donepezil 5 mg + PF-04995274 Placebo
- DRUG Scopolamine + Donepezil 10mg + PF-04995274 Placebo
- DRUG Scopolamine + Donepezil Placebo + PF-04995274 0.25 mg
- DRUG Scopolamine + Donepezil Placebo + PF-04995274 15 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2011-05 |
| Est. Completion | 2011-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01345864
The ClinicalTrials.gov registry entry for NCT01345864 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Scopolamine + Donepezil Placebo + PF-04995274 Placebo is the first listed.
NCT01345864 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01345864 about?
NCT01345864 is a clinical study titled "Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults". This study is designed to look at the potential for an investigational drug (PF-04995274, under development by Pfizer, Inc. as a potential treatment for Alzheimer's disease) to reverse changes in memory and learning/problem solving skills caused by co-administration of a marketed drug called scopola...
What is the current status of trial NCT01345864?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2011-05. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01345864?
The interventions under investigation include: Scopolamine + Donepezil Placebo + PF-04995274 Placebo (DRUG), Scopolamine + Donepezil 5 mg + PF-04995274 Placebo (DRUG), Scopolamine + Donepezil 10mg + PF-04995274 Placebo (DRUG), Scopolamine + Donepezil Placebo + PF-04995274 0.25 mg (DRUG), Scopolamine + Donepezil Placebo + PF-04995274 15 mg (DRUG).
Who is sponsoring clinical trial NCT01345864?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.